Vertex Pharmaceuticals Incorporated
VRTX
$493.84
$1.370.28%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 15.66% | 11.61% | 6.11% | 13.30% | 9.34% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 15.66% | 11.61% | 6.11% | 13.30% | 9.34% |
| Cost of Revenue | 5.41% | 12.39% | 22.32% | 12.11% | 22.02% |
| Gross Profit | 24.89% | 10.97% | -6.56% | 14.18% | -0.02% |
| SG&A Expenses | -6.53% | 40.94% | 41.74% | 42.14% | 38.03% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.59% | 17.80% | 26.07% | 17.90% | 25.46% |
| Operating Income | 37.02% | 3.72% | -17.72% | 8.18% | -9.63% |
| Income Before Tax | -0.97% | 3.81% | -391.97% | 43.48% | 6.58% |
| Income Tax Expenses | 25.00% | 24.18% | -17.66% | -6.36% | -30.67% |
| Earnings from Continuing Operations | -5.76% | 0.98% | -492.44% | 57.13% | 18.31% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.76% | 0.98% | -492.44% | 57.13% | 18.31% |
| EBIT | 37.02% | 3.72% | -17.72% | 8.18% | -9.63% |
| EBITDA | 32.70% | 4.56% | -16.03% | 9.17% | -8.49% |
| EPS Basic | -5.69% | 0.97% | -491.83% | 56.64% | 17.94% |
| Normalized Basic EPS | 27.15% | -0.14% | -15.27% | 10.08% | 0.43% |
| EPS Diluted | -5.64% | 1.01% | -495.55% | 56.51% | 18.08% |
| Normalized Diluted EPS | 27.25% | -0.29% | -14.39% | 10.08% | 0.52% |
| Average Basic Shares Outstanding | -0.08% | 0.00% | 0.16% | 0.31% | 0.31% |
| Average Diluted Shares Outstanding | -0.15% | 0.15% | -0.88% | 0.31% | 0.23% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |